Phase IIIb Study of Ribociclib + ET in Early Breast Cancer

IsraelRecruitingPHASE3

Conditions

Early Breast Cancer

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations
  • Central Alabama Research, Birmingham, Alabama, United States

    Contact: Study coordinator (Lorie Szymela) · LSzymela@centralalabamaresearch.com
    Contact: Principal Investigator (David Mooney)
  • Alaska Oncology and Hematology LLC, Anchorage, Alaska, United States

    Contact: Study coordinator (Talia Wyckoff) · talia@alaskaoncology.com · 907-279-3155
    Contact: Principal Investigator (Steven Liu)
  • Western Reg MC-COH Phoenix, Goodyear, Arizona, United States

    Contact: Study coordinator (Susan Sheerin-Fadden) · ssheerinfadden@coh.org · 623-207-3381
    Contact: Principal Investigator (Cynthia Lynch)
  • CARTI Cancer Center, Little Rock, Arkansas, United States

    Contact: Study coordinator (Emily Johnson) · Emily.Johnson@carti.com · 501-906-3000
    Contact: Principal Investigator (Issam Sam Makhoul)
  • Beverly Hills Cancer Center, Beverly Hills, California, United States

    Contact: Study coordinator (Carlos Jovel) · CJovel@bhcancercenter.com · 310-432-8900
    Contact: Principal Investigator (Linnea Chap)
  • Onco Inst of Hope and Innovation, Cerritos, California, United States

    Contact: Study coordinator (Sabrina Mora) · sabrina.mora@heliosclinical.com · 562-698-6888
    Contact: Principal Investigator (Pamela Miel)
  • City of Hope National Medical, Duarte, California, United States

    Contact: Study coordinator (Felicia Lewis) · flewis@coh.org · +1 6263598111#65994
    Contact: Principal Investigator (Thanh Nga Doan)
  • Providence Medical Foundation, Fullerton, California, United States

    Contact: Study coordinator (Teresa Olea) · teresa.olea@stjoe.org · 714-449-6200
    Contact: Principal Investigator (Giribala R Patel)
  • Palo Alto Medical Foundation, Mountain View, California, United States

    Contact: Study coordinator (Christine Lee) · christine.lee4@sutterhealth.org · 650-853-5763
    Contact: Principal Investigator (Natalia Colocci)
  • UC Irvine Medical Center, Orange, California, United States

    Contact: Study coordinator (Stephany Ruiz) · ruizs11@hs.uci.edu · 714-456-6288
    Contact: Principal Investigator (Ritesh Parajuli)
  • Sutter Inst Medical Research, Sacramento, California, United States

    Contact: Study coordinator (Clara Dunn) · dunncm@sutterhealth.org · 916-453-5742
    Contact: Principal Investigator (Nitin Rohatgi)
  • School Of Medicine, Sacramento, California, United States

    Contact: Study coordinator (Apinya Vorasaph) · avorasaph@health.ucdavis.edu
    Contact: Principal Investigator (Mili Arora)
  • Rocky Mountain Cancer Centers, Denver, Colorado, United States

    Contact: Study coordinator (Kathryn Wilson) · kathryn.wilson@usoncology.com · 303-321-0302
    Contact: Principal Investigator (Mabel Mardones)
  • Georgetown University Lombardi Cancer Center, Washington D.C., District of Columbia, United States

    Contact: Study coordinator (Julie Castle) · bickmorj@georgetown.edu · 202-687-8676
    Contact: Principal Investigator (Katia Khoury)
  • Washington Hospital Center, Washington D.C., District of Columbia, United States

    Contact: Study coordinator (Stacy Malloy) · Stacy.K.Malloy@medstar.net · 202-877-2146
    Contact: Principal Investigator (Ami Chitalia)
  • AdventHealth Altamonte Springs, Altamonte Springs, Florida, United States

    Contact: Study coordinator (Rebecca Iorio) · rebecca.iorio@adventhealth.com
    Contact: Principal Investigator (Wassim Mchayleh)
  • Holy Cross Health, Fort Lauderdale, Florida, United States

    Contact: Study coordinator (Eileen Georgi) · Eileen.Georgi@holy-cross.com · 954-771-8000
    Contact: Principal Investigator (Karim Arnaout)
  • Hialeah Hospital, Hialeah, Florida, United States

    Contact: Study coordinator (Jonathan Matias) · jmatias@bioresearchpartner.com
    Contact: Principal Investigator (Luis G Rangel)
  • Memorial Cancer Institute, Hollywood, Florida, United States

    Contact: Study coordinator (Florencia Brunengo) · fbrunengo@mhs.net
    Contact: Principal Investigator (Adriana Milillo Naraine)
  • Jupiter Medical Center, Jupiter, Florida, United States

    Contact: Study coordinator (Christine Leonard) · christine.leonard@jupitermed.com · 561-263-5768
    Contact: Principal Investigator (Danielle Krol)
  • Ocala Research Institute, Inc, Ocala, Florida, United States

    Contact: Study coordinator (Michelle Jackson) · Michelle.Jackson@usoncology.com · 352-351-7126
    Contact: Principal Investigator (Anju Vasudevan)
  • University Cancer and Blood Center LLC, Athens, Georgia, United States

    Contact: Study coordinator (Christen Nicole Cooper Pope) · npope@universitycancer.com
    Contact: Principal Investigator (Amanda Hathaway)
  • Summit Cancer Care PC, Savannah, Georgia, United States

    Contact: Study coordinator (Theresa Williams) · twilliams@summitcancercare.com
    Contact: Principal Investigator (Mark A Taylor)
  • Hawaii Cancer Care, Honolulu, Hawaii, United States

    Contact: Study coordinator (Angelei Gommesen) · AngeleiJan.Gommesen@aoncology.com
    Contact: Principal Investigator (Arnold K N Yee)
  • Affiliated Oncologists IL, Chicago, Illinois, United States

    Contact: Study coordinator (Angela Malone) · angela.malone@usoncology.com
    Contact: Principal Investigator (Rami Haddad)
  • Hope And Healing Care, Hinsdale, Illinois, United States

    Contact: Study coordinator (Divya Mudavath) · dmudavath@hopenheal.care
    Contact: Principal Investigator (Srilata Gundala)
  • Midwestern Reg MC COH Chicago, Zion, Illinois, United States

    Contact: Study coordinator (Afua Amoabin) · aamoabin@coh.org · 847-872-4561
    Contact: Principal Investigator (Ajaz Khan)
  • Investigative Clinical R of Indiana, Indianapolis, Indiana, United States

    Contact: Study coordinator (Zara Edgell) · zedgell@investigativeicr.com
    Contact: Principal Investigator (Ruemu Birhiray)
  • University of Iowa Health Care, Waukee, Iowa, United States

    Contact: Study coordinator (Theresa Caon) · tcaon@missioncancer.com
    Contact: Principal Investigator (Seema Harichand-Herdt)
  • University of Kansas Cancer Center, Westwood, Kansas, United States

    Contact: Study coordinator (Chasity Cupp) · ccupp@kumc.edu
    Contact: Principal Investigator (Priyanka Sharma)
  • Cancer Center of Kansas, Wichita, Kansas, United States

    Contact: Study coordinator (Michelle Comstock) · michelle.comstock@cancercenterofkansas.com · 316-262-4467
    Contact: Principal Investigator (Shaker R Dakhil)
  • Willis-Knighton Cancer Center, Shreveport, Louisiana, United States

    Contact: Study coordinator (Briana Barrow) · bbarrow@wkhs.com
    Contact: Principal Investigator (Prakash Peddi)
  • Mercy Medical Center, Baltimore, Maryland, United States

    Contact: Study coordinator (Alexandra Cline) · acline@mdmercy.com · +1 410 332 1200
    Contact: Principal Investigator (David Andrew Riseberg)
  • Maryland Oncology Hematology P A, Silver Spring, Maryland, United States

    Contact: Study coordinator (Teresa Saavedra) · teresa.saavedra@usoncology.com
    Contact: Principal Investigator (Carol Tweed)
  • Boston Medical Center, Boston, Massachusetts, United States

    Contact: Study coordinator (Tara Hassani Goodarzi) · tara.hassanigoodarzi@bmc.org
    Contact: Principal Investigator (Jose J Acevedo)
  • Dana Farber Cancer Institute, Boston, Massachusetts, United States

    Contact: Study coordinator (Celine Ibrahim) · celine_ibrahim@dfci.harvard.edu · 617-632-5607
    Contact: Principal Investigator (Erica Mayer)
  • Dana Farber Brigham Women Cancer, Milford, Massachusetts, United States

    Contact: Study coordinator (Laura Melancon) · laurae_melancon@dfci.harvard.edu · 617-732-9850
    Contact: Principal Investigator (Natalie Sinclair)
  • Minnesota Oncology Hematology P A, Minneapolis, Minnesota, United States

    Contact: Study coordinator (Anne Rabenn) · Anne.rabenn@usoncology.com
    Contact: Principal Investigator (Eric Lander)
  • Allina Hlth Cancer Inst Minneapolis, Minneapolis, Minnesota, United States

    Contact: Study coordinator (Jonathan Alexander) · jonathan.alexander@allina.com · 612-863-9466
    Contact: Principal Investigator (Daniel Carlson)
  • Jackson Oncology Associates, Jackson, Mississippi, United States

    Contact: Study coordinator (Teresa Davis) · tdavis@jacksononcology.com · 601-974-5547
    Contact: Principal Investigator (Justin T Baker)
  • HCA Midwest Division, Kansas City, Missouri, United States

    Contact: Study coordinator (Katie Burnside) · katherine.burnside@hcahealthcare.com
    Contact: Principal Investigator (Anis Toumeh)
  • WA Uni School Of Med, St Louis, Missouri, United States

    Contact: Study coordinator (Elizabeth Ainsworth) · ainsworth@wustl.edu · 314-747-8085
    Contact: Principal Investigator (Katherine Clifton)
  • Intermountain Healthcare, Billings, Montana, United States

    Contact: Study coordinator (Kelsi Margaris) · kelsi.margaris@imail.org
    Contact: Principal Investigator (Patrick Cobb)
  • Nebraska Cancer Specialists, Omaha, Nebraska, United States

    Contact: Study coordinator (Heather Cordes) · hcordes@nebraskacancer.com · +1 402 334 4773
    Contact: Principal Investigator (Margaret Barbara Block)
  • Renown Regional Medical Center, Reno, Nevada, United States

    Contact: Study coordinator (Bayley Stoner) · Bayley.Stoner@renown.org
    Contact: Principal Investigator (Lee Schwartzberg)
  • Cancer Care Specialists, Reno, Nevada, United States

    Contact: Study coordinator (Layla Quinonez) · Lquinonez@ccsreno.com
    Contact: Principal Investigator (Sowjanya Reganti)
  • Summit Health, Florham Park, New Jersey, United States

    Contact: Study coordinator (Mehmet Kurt) · mkurt4@summithealth.com · 973-538-5210
    Contact: Principal Investigator (Steven Papish)
  • The Valley Hospital, Ridgewood, New Jersey, United States

    Contact: Study coordinator (Emily Clark) · eclark2@valleyhealth.com
    Contact: Principal Investigator (Amanda Podolski)
  • Presbyterian Medical Group, Albuquerque, New Mexico, United States

    Contact: Study coordinator (Monique Robertson) · mrobertso2@phs.org · 505-559-6100
    Contact: Principal Investigator (Yashvin Onkarappa Mangala)
  • Queens Cancer Center of Queens Hospital, Jamaica, New York, United States

    Contact: Study coordinator (Linda Bulone) · buLoneL@nychhc.org · 718-883-3751
    Contact: Principal Investigator (Ellen Hagopian)
  • Optum Health, Lake Success, New York, United States

    Contact: Study coordinator (Rabia Khan) · rabia.khan2@uhn.ca · +1 516 488 2918#183
    Contact: Principal Investigator (Jonathan Goldberg)
  • Mount Sinai School of Medicine, New York, New York, United States

    Contact: Study coordinator (Weronika Bucwinska) · weronika.bucwinska@mssm.edu
    Contact: Principal Investigator (Melanie Kier)
  • Duke Cancer Network, Durham, North Carolina, United States

    Contact: Study coordinator (Catrin Davies) · catrin.davies@duke.edu
    Contact: Principal Investigator (Madhu Chaudhry)
  • Cone Health Cancer Center, Greensboro, North Carolina, United States

    Contact: Study coordinator (Nikki Eldreth) · Nikki.Eldreth@conehealth.com · 336-832-1100
    Contact: Principal Investigator (Vinay Gudena)
  • Sanford Research USD Fargo, Fargo, North Dakota, United States

    Contact: Study coordinator (Riley Klueber) · riley.klueber@sanfordhealth.org · 701-234-2371
    Contact: Principal Investigator (Anu Goel Gaba)
  • Good Samaritan Regional Medical Center, Corvallis, Oregon, United States

    Contact: Study coordinator (Esther VanTil) · evantil@samhealth.org · 541-768-5800
    Contact: Principal Investigator (John Strother)
  • Oncology Associates of Oregon PC, Eugene, Oregon, United States

    Contact: Study coordinator (Spencer Dandy) · Spencer.dandy@usoncology.com
    Contact: Principal Investigator (Miho Dougherty)
  • Northwest Cancer Specialists, Portland, Oregon, United States

    Contact: Study coordinator (Heather Firneisz) · Heather.Firneisz@usoncology.com · 971-708-7600
    Contact: Principal Investigator (Jay Andersen)
  • Oregon Oncology Specialists Salem, Salem, Oregon, United States

    Contact: Study coordinator (Kyla Kinney) · kkinney@orcancer.com
    Contact: Principal Investigator (Janelle Meyer)
  • Consultants In Med Onco And Hema, Drexel Hill, Pennsylvania, United States

    Contact: Study coordinator (Maureen Lisowski) · maureen.Lisowski@usoncology.com
    Contact: Principal Investigator (Alexander Deak)
  • Univ of Pittsburg Med Ctr Pinnacle, Harrisburg, Pennsylvania, United States

    Contact: Study coordinator (Bridgett West) · westb@upmc.edu · 717-652-3000
    Contact: Principal Investigator (Marija Balic)
  • Rhode Island Hospital, Providence, Rhode Island, United States

    Contact: Study coordinator (Janine Grigelevich) · jgrigelevich@brownhealth.org · 401-444-7525
    Contact: Principal Investigator (Stephanie Graff)
  • Bon Secours St Francis Cancer Center, Greenville, South Carolina, United States

    Contact: Study coordinator (Christine Sanchez) · Christine_Sanchez@bshsi.org · +1 864 603 6214
    Contact: Principal Investigator (Stephen Howard Dyar)
  • Lexington Medical Center, West Columbia, South Carolina, United States

    Contact: Study coordinator (Katharine Madden) · kdmadden@lexhealth.org · 803-794-7511
    Contact: Principal Investigator (Steven Madden)
  • Regional Medical Oncology NC, Wilson, South Carolina, United States

    Contact: Study coordinator (Merdith Best) · meredith.best@regionaloncology.com
    Contact: Principal Investigator (Keith Lerro)
  • Sanford USD Medical Center, Sioux Falls, South Dakota, United States

    Contact: Study coordinator (Jane Veerman) · jane.veerman@sanfordhealth.org · 605-328-8000
    Contact: Principal Investigator (Allison Watson)
  • Sarah Cannon Research Institute, Nashville, Tennessee, United States

    Contact: Study coordinator (Madeleine Enos) · madeleine.enos@scri.com · 615-329-7270
    Contact: Principal Investigator (Denise A Yardley)
  • El Paso Texas Oncology, El Paso, Texas, United States

    Contact: Study coordinator (Mary Williams) · mary.williams2@usoncology.com
    Contact: Principal Investigator (Ines Sanchez-Rivera)
  • Kelsey Seybold Clinic, Houston, Texas, United States

    Contact: Study coordinator (Shawndra Alexander) · shawndra.alexander@kelseyresearch.com · 713-442-1224
    Contact: Principal Investigator (Sunil Patel)
  • University of Texas, Houston, Texas, United States

    Contact: Study coordinator (Cynthia Tamez) · ctamez@mdanderson.org · 713-794-5783
    Contact: Principal Investigator (Jason Mouabbi)
  • Texas Oncology P A Plano East, Plano, Texas, United States

    Contact: Study coordinator (Kristy Dillard) · Kristy.Dillard@usoncology.com · 972-867-3577
    Contact: Principal Investigator (Carlos Taboada)
  • Texas Oncology PA Tyler, Tyler, Texas, United States

    Contact: Study coordinator (Jennifer Castner) · jennifer.castner@usoncology.com
    Contact: Principal Investigator (Nanna Sulai)
  • Bon Secours Virginia Health System, Midlothian, Virginia, United States

    Contact: Study coordinator (Mary M Williams) · Mary_Williams7@bshsi.org · 804-894-8665
    Contact: Principal Investigator (William Irvin)
  • Virginia Oncology Associates, Norfolk, Virginia, United States

    Contact: Study coordinator (Patricia Innis-Deleon) · patricia.deleon@usoncology.com
    Contact: Principal Investigator (Michael A Danso)
  • Kadlec Clinic Hematology and Onco, Kennewick, Washington, United States

    Contact: Study coordinator (Heather Harris) · heather.e.harris@kadlec.org · 509-783-0144
    Contact: Principal Investigator (Ying Zhuo)
  • Providence Regional Cancer System, Lacey, Washington, United States

    Contact: Study coordinator (Deidre Dillon) · deidre.dillon@providence.org · 360-754-3934
    Contact: Principal Investigator (Mijung Lee)
  • Valley Medical Center Research, Renton, Washington, United States

    Contact: Study coordinator (Dione Froman) · Dione_Froman@valleymed.org
    Contact: Principal Investigator (Navanshu Arora)
  • Northwest Medical Specialties, Tacoma, Washington, United States

    Contact: Study coordinator (Patricia Walsh) · pwalsh@nwmsonline.com · 253-428-8756
    Contact: Principal Investigator (Sibel Blau)
  • Novartis Investigative Site, Caba, Buenos Aires, Argentina

  • Novartis Investigative Site, La Plata, Buenos Aires, Argentina

  • Novartis Investigative Site, Córdoba, Argentina

  • Novartis Investigative Site, Gateshead, New South Wales, Australia

  • Novartis Investigative Site, Tiwi, Northern Territory, Australia

  • Novartis Investigative Site, Clayton, Victoria, Australia

  • Novartis Investigative Site, East Melbourne, Victoria, Australia

  • Novartis Investigative Site, Salvador, Estado de Bahia, Brazil

  • Novartis Investigative Site, Salvador, Estado de Bahia, Brazil

  • Novartis Investigative Site, Porto Alegre, Rio Grande do Sul, Brazil

  • Novartis Investigative Site, Porto Alegre, Rio Grande do Sul, Brazil

  • Novartis Investigative Site, São Paulo, São Paulo, Brazil

  • Novartis Investigative Site, São Paulo, Brazil

  • Novartis Investigative Site, Victoria, British Columbia, Canada

  • Novartis Investigative Site, Halifax, Nova Scotia, Canada

  • Novartis Investigative Site, Oakville, Ontario, Canada

  • Novartis Investigative Site, Ottawa, Ontario, Canada

  • Novartis Investigative Site, Toronto, Ontario, Canada

  • Novartis Investigative Site, Montreal, Quebec, Canada

  • Novartis Investigative Site, Montreal, Quebec, Canada

  • Novartis Investigative Site, Montreal, Quebec, Canada

  • Novartis Investigative Site, Québec, Quebec, Canada

  • Novartis Investigative Site, Saskatoon, Saskatchewan, Canada

  • Novartis Investigative Site, Beijing, Beijing Municipality, China

  • Novartis Investigative Site, Guangzhou, Guangdong, China

  • Novartis Investigative Site, Harbin, Heilongjiang, China

  • Novartis Investigative Site, Zhengzhou, Henan, China

  • Novartis Investigative Site, Zhengzhou, Henan, China

  • Novartis Investigative Site, Nanjing, Jiangsu, China

  • Novartis Investigative Site, Nanchang, Jiangxi, China

  • Novartis Investigative Site, Changchun, Jilin, China

  • Novartis Investigative Site, Jinan, Shandong, China

  • Novartis Investigative Site, Jinan, Shandong, China

  • Novartis Investigative Site, Jining, Shandong, China

  • Novartis Investigative Site, Chengdu, Sichuan, China

  • Novartis Investigative Site, Chengdu, Sichuan, China

  • Novartis Investigative Site, Ürümqi, Xinjiang, China

  • Novartis Investigative Site, Hangzhou, Zhejiang, China

  • Novartis Investigative Site, Hangzhou, Zhejiang, China

  • Novartis Investigative Site, Wenzhou, Zhejiang, China

  • Novartis Investigative Site, Beijing, China

  • Novartis Investigative Site, Beijing, China

  • Novartis Investigative Site, Guangzhou, China

  • Novartis Investigative Site, Qingdao, China

  • Novartis Investigative Site, Shanghai, China

  • Novartis Investigative Site, Shijiazhuang, China

  • Novartis Investigative Site, Tianjin, China

  • Novartis Investigative Site, Freiburg im Breisgau, Baden-Wurttemberg, Germany

  • Novartis Investigative Site, Munich, Bavaria, Germany

  • Novartis Investigative Site, Regensburg, Bavaria, Germany

  • Novartis Investigative Site, Weiden in Der Oberpfalz, Bavaria, Germany

  • Novartis Investigative Site, Langen, Hesse, Germany

  • Novartis Investigative Site, Hildesheim, Lower Saxony, Germany

  • Novartis Investigative Site, Bergisch Gladbach, North Rhine-Westphalia, Germany

  • Novartis Investigative Site, Bielefeld, North Rhine-Westphalia, Germany

  • Novartis Investigative Site, Düsseldorf, North Rhine-Westphalia, Germany

  • Novartis Investigative Site, Essen, North Rhine-Westphalia, Germany

  • Novartis Investigative Site, Mönchengladbach, North Rhine-Westphalia, Germany

  • Novartis Investigative Site, Velbert, North Rhine-Westphalia, Germany

  • Novartis Investigative Site, Dresden, Saxony, Germany

  • Novartis Investigative Site, Lübeck, Schleswig-Holstein, Germany

  • Novartis Investigative Site, Augsburg, Germany

  • Novartis Investigative Site, Augsburg, Germany

  • Novartis Investigative Site, Berlin, Germany

  • Novartis Investigative Site, Berlin, Germany

  • Novartis Investigative Site, Bottrop, Germany

  • Novartis Investigative Site, Böblingen, Germany

  • Novartis Investigative Site, Dessau, Germany

  • Novartis Investigative Site, Erlangen, Germany

  • Novartis Investigative Site, Essen, Germany

  • Novartis Investigative Site, Hamburg, Germany

  • Novartis Investigative Site, Kiel, Germany

  • Novartis Investigative Site, Leipzig, Germany

  • Novartis Investigative Site, Mainz, Germany

  • Novartis Investigative Site, München, Germany

  • Novartis Investigative Site, Ravensburg, Germany

  • Novartis Investigative Site, Hong Kong, Hong Kong

  • Novartis Investigative Site, Kowloon, Hong Kong

  • Novartis Investigative Site, Tuenmen, Hong Kong

  • Novartis Investigative Site, Hyderabad, Andhra Pradesh, India

  • Novartis Investigative Site, Bangalore, Karnataka, India

  • Novartis Investigative Site, Mumbai, Maharashtra, India

  • Novartis Investigative Site, Pune, Maharasthra, India

  • Novartis Investigative Site, New Delhi, National Capital Territory of Delhi, India

  • Novartis Investigative Site, Bhubaneswar, Odisha, India

  • Novartis Investigative Site, Chennai, Tamil Nadu, India

  • Novartis Investigative Site, Kolkata, West Bengal, India

  • Novartis Investigative Site, Ahmedabad, India

  • Novartis Investigative Site, Beersheba, Israel

  • Novartis Investigative Site, Petah Tikva, Israel

  • Novartis Investigative Site, Ramat Gan, Israel

  • Novartis Investigative Site, Tel Aviv, Israel

  • Novartis Investigative Site, Alc Cuahutemoc, Mexico City, Mexico

  • Novartis Investigative Site, Tlalpan, Mexico City, Mexico

  • Novartis Investigative Site, Monterrey, Nuevo León, Mexico

  • Novartis Investigative Site, Coimbra, Portugal

  • Novartis Investigative Site, Lisbon, Portugal

  • Novartis Investigative Site, Lisbon, Portugal

  • Novartis Investigative Site, Porto, Portugal

  • Novartis Investigative Site, Porto, Portugal

  • Novartis Investigative Site, Porto, Portugal

  • Pan Oncology, Rio Piedras, Puerto Rico

    Contact: Study coordinator (Nathalia Verge) · nathalia.verge@panoncologytrials.com · +1 787 407 3333
    Contact: Principal Investigator (Omayra Gonzalez Rodriguez)
  • Novartis Investigative Site, Bundang Gu, Gyeonggi-do, South Korea

  • Novartis Investigative Site, Gyeonggi-do, Korea, South Korea

  • Novartis Investigative Site, Incheon, Korea, South Korea

  • Novartis Investigative Site, Seoul, Korea, South Korea

  • Novartis Investigative Site, Seoul, Yangcheon Gu, South Korea

  • Novartis Investigative Site, Seongnam Gyeonggi, South Korea

  • Novartis Investigative Site, Seoul, South Korea

  • Novartis Investigative Site, Seoul, South Korea

  • Novartis Investigative Site, Seoul, South Korea

  • Novartis Investigative Site, Seoul, South Korea

  • Novartis Investigative Site, Seoul, South Korea

  • Novartis Investigative Site, Seoul, South Korea

  • Novartis Investigative Site, Hualien City, Taiwan

  • Novartis Investigative Site, Kaohsiung City, Taiwan

  • Novartis Investigative Site, Tainan, Taiwan

  • Novartis Investigative Site, Taipei, Taiwan

  • Novartis Investigative Site, Taipei, Taiwan

  • Novartis Investigative Site, Sakarya, Adapazari, Turkey (Türkiye)

  • Novartis Investigative Site, Ankara, Bilkent-Cankaya, Turkey (Türkiye)

  • Novartis Investigative Site, Istanbul, Fatih, Turkey (Türkiye)

  • Novartis Investigative Site, Istanbul, Kadikoy, Turkey (Türkiye)

  • Novartis Investigative Site, Izmir, Karsiyaka, Turkey (Türkiye)

  • Novartis Investigative Site, Denizli, Kinikli, Turkey (Türkiye)

  • Novartis Investigative Site, Antalya, Konyaalti, Turkey (Türkiye)

  • Novartis Investigative Site, Istanbul, Sariyer, Turkey (Türkiye)

  • Novartis Investigative Site, Ankara, Sihhiye-Altindag, Turkey (Türkiye)

  • Novartis Investigative Site, Diyarbakır, Sur, Turkey (Türkiye)

  • Novartis Investigative Site, Istanbul, Uskudar, Turkey (Türkiye)

  • Novartis Investigative Site, Ankara, Yenimahalle, Turkey (Türkiye)

  • Novartis Investigative Site, Ankara, Yenimahalle, Turkey (Türkiye)

  • Novartis Investigative Site, Adana, Yuregir, Turkey (Türkiye)

  • Novartis Investigative Site, Ankara, Turkey (Türkiye)

  • Novartis Investigative Site, Istanbul, Turkey (Türkiye)

  • Novartis Investigative Site, Izmir, Turkey (Türkiye)

  • Novartis Investigative Site, Kecioren Ankara, Turkey (Türkiye)

  • Novartis Investigative Site, Konya, Turkey (Türkiye)

  • Novartis Investigative Site, Samsun, Turkey (Türkiye)

Study leads
  • Novartis Pharmaceuticals

    Study Director

    Novartis Pharmaceuticals